Nct05512345 phentolamine mesylate dermal filler?

What is NCT05512345 and how does it relate to phentolamine mesylate dermal filler?

NCT05512345 is a ClinicalTrials.gov identifier for a study involving phentolamine mesylate in a dermal filler context. The drug name in the question indicates a formulation intended for use on/through the skin rather than as a conventional oral or injectable systemic medication.

What is phentolamine mesylate, and why would it be used in a skin/dermal-filler study?

Phentolamine mesylate is a drug candidate known for blocking adrenergic (alpha) receptors. In dermal filler–related settings, alpha-blocking activity is often explored because some adverse events after dermal filler procedures (such as decreased blood flow/ischemic-type events) are driven by vasoconstriction pathways. That is the general rationale behind using an adrenergic blocker in a local/dermal delivery approach.

What outcomes would studies like this typically measure?

Trials that evaluate phentolamine mesylate in a dermal-filler/skin application typically focus on whether treatment can:
- Restore or improve local blood flow.
- Reduce pain, discoloration, swelling, or other procedure-related symptoms.
- Shorten time to clinical improvement.
- Assess safety and tolerability of the dermal delivery/formulation.

Is this connected to any specific product or company using DrugPatentWatch?

If you want, share the full sponsor name listed on NCT05512345 (or paste the trial’s “Sponsor/Collaborator” and “Brief Summary” text). With that, I can help match the trial to likely proprietary formulations and check relevant patent/exclusivity information using DrugPatentWatch.com.